ARTMS and Isotopia Announce successful Multi-Curie Labeling of PSMA-11

artms collaboration post - Isotopia

ARTMS and Isotopia are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system.

The specially designed Prostate-Specific Membrane Antigen (PSMA) kit for the preparation of 68Ga-PSMA-11 (a radiopharmaceutical targeting PSMA for the imaging of prostate cancer using Positron Emission Tomography (PET) was radiolabeled with high activity cyclotron produced 68Ga following irradiation times of less than two hours.

The Isotopia kit was radiolabeled with between 500 mCi and just over 2900 mCi of 68Ga following multiple successful 68Ga production runs utilizing the QISTM and ARTMS’ high performance 68Zn solid targets.  The resultant product demonstrated 6-hour stability and radiochemical purity, which met or exceeded all regulatory standards. Cyclotron produced 68Ga combined with a kit solution will give radiopharmacies near unlimited access to this diagnostic product and a cost effective solution.

 “The demand for 68Ga radiolabeled products will soon exceed the supply coming from 68Ge/68Ga generators.

ARTMS’ QUANTM Irradiation System™ (QIS™) allows for the high activity and high quality 68Ga production the Molecular Imaging community requires to properly serve their patients.  

The QIS™’ multiple-curie per hour 68Ga production is one of the few true game changers I have seen during my career in Nuclear Medicine. We are very excited to bring on-demand 68Ga doses to clinicians and patients in collaboration with our partners,” says Charles S. Conroy, Chief Executive Officer of ARTMS.

 “Isotopia is focused on developing diagnostic and therapeutic tools that best serve our patients. We see 68Ga as a better diagnostic tool to pair with Lu177 treatments.  Isotopia’s high activity PSMA “kit” is a major step forward in how the global imaging community diagnoses prostate cancer. 

Multi-dose vial preparation will allow pharmacies to provide unit doses and allow clinicians to image patients with little to no restrictions. In addition, a 5 minute preparation and more than 95% radiochemical purity will enhance efficiency and save the radiopharmacies time and money. 

We aim to keep introducing to the market kit-based solutions for 50 and 100mCi Generators, cyclotron produced 68Ga, and Lu177 labeling,” says Dr. Eli Shalom, CEO of Isotopia.

ARTMS recently announced the approval for its cyclotron produced 99mTc product by Health Canada.  ARTMS will continue the development of cyclotron-based products including 68Ga with a focus on optimizing production potential and satisfying regulatory requirements for use in radiopharmaceutical kits.

About Prostate Cancer

Prostate cancer is the fourth most common cancer worldwide. In 2018, 1.3 million men were diagnosed with prostate cancer for the first time.  Despite advances in treatments, prostate cancer still accounts for a significant number of deaths. In 2018, more than 365,000 men died from the disease.  Rates of diagnosis are increasing, and the highest levels of prostate cancer are found in the US, Europe, Australia, and New Zealand.

For further information, please contact:              

ARTMS Corporate Contact

Charles S. Conroy R.Ph, MBA


Chief Executive Officer


ARTMS Business Contact

Doug Gentilcore


Chief Commercial Officer


Isotopia  Corporate Contact

Dr. Eli Shalom, PhD


Chief Executive Officer


Isotopia Business Contact

Keren Moshkoviz


Director of Business Development


About ARTMS Inc

Based in Vancouver, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes.  ARTMS’ flagship product, the QUANTM Irradiation SystemTM (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as  gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using  pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain.  ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.

About Isotopia

Isotopia Ltd. is a collaboration between The Metrontario Group and some of Israel’s leading scientists in the field of radiopharmaceuticals.  The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers, and physicists.  The experienced Isotopia team, together with its radio-nuclear pharmacy, cyclotron facility, 177Lu production site and sterile manufacturing, are a well-established platform for development.  Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

More To Explore